Welcome to our dedicated page for Koninklijke Phil SEC filings (Ticker: PHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Koninklijke Philips N.V. (Royal Philips, NYSE: PHG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Philips files annual reports on Form 20-F and interim reports on Form 6-K, which include detailed information on its health technology business spanning diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health.
In its Form 6-K quarterly reports, Philips presents group and segment performance, including comparable order intake growth, comparable sales growth, income from operations, adjusted EBITA margin and free cash flow. The filings break down results for the Diagnosis & Treatment, Connected Care and Personal Health segments, and provide sales by geographic area such as Western Europe, North America, other mature geographies and growth geographies. Management commentary explains how innovation, product mix, productivity measures and tariffs influence margins and cash flow.
These filings also describe innovation highlights and portfolio changes. Examples disclosed in recent 6-Ks and related reports include AI-powered imaging and image-guided therapy solutions, spectral CT and MRI platforms, monitoring partnerships, and productivity programs. Capital allocation topics such as dividend distributions, bond issuance, and productivity targets are discussed, along with notes on ongoing matters like Respironics-related proceedings and insurance income.
Stock Titan enhances access to Philips filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify trends in orders, sales, margins and cash generation. Real-time updates from EDGAR ensure that new Form 6-K submissions and other relevant filings are available as they are published. Users can review historical filings to analyze how segment performance, geographic mix and strategic priorities have evolved over time.
For investors, analysts and healthcare professionals, this page offers a structured view of Philips’ official financial and operational disclosures, supported by AI summaries to make complex SEC filings more approachable.
Koninklijke Philips reports 2025 sales of EUR 17.8 billion, down 1% nominally but up 2% on a comparable basis, with growth in Connected Care and Personal Health offsetting flat Diagnosis & Treatment. Net income recovered to EUR 897 million from a EUR 698 million loss in 2024.
Adjusted EBITA rose to EUR 2.2 billion, or 12.3% of sales, driven by higher gross margins, productivity measures and sharply lower Respironics-related and restructuring charges. Free cash flow reached EUR 512 million, and the company proposes maintaining a dividend of EUR 0.85 per share in cash or stock.
Philips highlights innovation in AI-enabled imaging, monitoring and personal health, progress on Respironics remediation, and a streamlined operating model after completing a 10,000-role workforce reduction. For 2026, it targets 3–4.5% comparable sales growth, a 12.5–13.0% adjusted EBITA margin and EUR 1.3–1.5 billion free cash flow.
Royal Philips reports 2025 sales of EUR 17.8 billion, down 1% nominally but up 2% on a comparable basis, with strong growth in Personal Health and Connected Care offsetting flat Diagnosis & Treatment. The company improved income from operations to EUR 1,424 million, or 8% of sales, and returned to profitability with net income of EUR 897 million, compared with a loss in 2024.
Adjusted EBITA rose to EUR 2,195 million, a 12.3% margin, helped by productivity programs, mix improvements and lower Respironics-related charges, despite higher tariffs and inflation. Free cash flow was EUR 512 million. Philips targets 2026 comparable sales growth of 3%–4.5%, an adjusted EBITA margin of 12.5%–13.0%, and EUR 1.3–1.5 billion free cash flow, and outlines 2026–2028 ambitions for mid-single-digit growth and mid-teens margins while continuing to execute under the US Respironics consent decree.
Royal Philips plans to propose the re-appointment of Roy Jakobs as President/CEO and Board of Management member, with shareholder approval to be sought at the Annual General Meeting on May 8, 2026.
The Supervisory Board cites progress since 2022, including addressing the Respironics recall, strengthening patient safety and quality culture, simplifying the organization, and achieving EUR 2.5 billion in productivity savings. It highlights restored company growth, materially higher margins and positive cash generation supporting a robust balance sheet.
Philips, a global health technology company focused on diagnostic imaging, monitoring and personal health, reports 2024 sales of EUR 18 billion and around 67,000 employees in more than 100 countries.
Koninklijke Philips N.V. reported a strong turnaround in 2025, moving from a net loss of EUR 698 million in 2024 to net income of EUR 897 million, with diluted EPS from continuing operations at EUR 0.93. Sales were EUR 17.8 billion with 2% comparable growth, while the Adjusted EBITA margin improved to 12.3% from 11.5%, reflecting better gross margins and EUR 0.8 billion of productivity savings in 2025.
In Q4 2025, comparable sales grew 7% and Adjusted EBITA margin rose to 15.1%, supported by double‑digit growth in Personal Health and solid performance in Connected Care. Free cash flow reached EUR 512 million for the year and EUR 1.2 billion in Q4, despite a EUR 1,025 million cash payment for Respironics recall‑related settlements. Philips proposes a 2025 dividend of EUR 0.85 per share, and guides for 2026 comparable sales growth of 3%–4.5%, an Adjusted EBITA margin of 12.5%–13.0%, and free cash flow of EUR 1.3–1.5 billion. The company also laid out 2026–2028 mid‑term targets, including mid‑single‑digit comparable sales growth and a mid‑teens Adjusted EBITA margin by 2028.
Koninklijke Philips N.V. reported Q3 2025 results showing continued momentum: comparable order intake grew 8% and group sales were EUR 4.3 billion, up 3.3% on a comparable basis. Income from operations was EUR 330 million. The adjusted EBITA margin rose 50 bps to 12.3% as higher sales, mix and productivity more than offset tariff headwinds.
Operating cash flow was EUR 327 million with free cash flow of EUR 172 million. Segment trends were mixed: Diagnosis & Treatment comparable sales grew 1.3% with margin at 11.8% (down 80 bps), Connected Care grew 5.1% with margin up 410 bps to 11.4%, and Personal Health grew 10.9% with margin at 17.1%.
Philips reiterated its full‑year 2025 outlook: comparable sales growth of 1%–3%, adjusted EBITA margin of 11.3%–11.8% now expected toward the upper end, and free cash flow of EUR 0.2–0.4 billion, which includes the EUR 1,025 million settlements paid in Q1 2025. The outlook excludes ongoing Philips Respironics‑related proceedings.